Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) will host an online webinar on March 19, 2026, as the company updates investors on progress across its anti-infective portfolio.
The webinar will be held via Zoom at 10:30am AEDT and will be recorded for those unable to attend live.
Presentations are set to cover key program areas including Recce’s registrational Phase 3 clinical trial for diabetic foot infections in Indonesia and its US Department of War burn wound program.
Speakers will also provide updates on its broader anti-infective portfolio, spanning clinical and pre-clinical programs, as well as other operational developments.
Presentation slides are expected to be released to the ASX before the webinar, with a full recording to be made available on Recce Pharmaceuticals’ website after the event.
To register for the webinar, click on the link here.
Recce signs US Army research agreement to test burn wound treatment
Last month, Recce entered a second agreement with the United States Army Institute of Surgical Research (USAISR), this time through a Cooperative Research and Development Agreement (CRADA), to evaluate its RECCE® 327 Gel (R327G) as a treatment for infected burn wounds.
Under the agreement, USAISR will assess R327G using its validated Walker-Mason rat model of burn wound infection, which is designed to replicate battlefield injuries and the systemic responses associated with burns and subsequent infections.